Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Average Price Target from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has been given a consensus rating of "Buy" by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $147.50.

A number of equities research analysts have issued reports on PCVX shares. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Leerink Partners lifted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 3rd. Bank of America boosted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd.

Vaxcyte Price Performance

NASDAQ PCVX traded down $3.18 during mid-day trading on Thursday, reaching $87.87. The stock had a trading volume of 879,061 shares, compared to its average volume of 904,119. The company has a fifty day moving average price of $102.04 and a 200 day moving average price of $91.41. Vaxcyte has a 1 year low of $53.83 and a 1 year high of $121.06. The stock has a market cap of $10.95 billion, a PE ratio of -19.79 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) earnings per share. As a group, equities research analysts expect that Vaxcyte will post -4.14 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 42,000 shares of the company's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at $10,429,294.37. This represents a 31.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the firm's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $91.49, for a total transaction of $457,450.00. Following the completion of the transaction, the senior vice president now directly owns 28,697 shares of the company's stock, valued at approximately $2,625,488.53. This trade represents a 14.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 117,830 shares of company stock worth $12,600,310. 3.10% of the stock is owned by insiders.

Institutional Trading of Vaxcyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Riverview Trust Co purchased a new stake in shares of Vaxcyte in the third quarter worth approximately $27,000. Fifth Third Bancorp bought a new position in Vaxcyte in the 2nd quarter worth about $35,000. Blue Trust Inc. increased its stake in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the period. J.Safra Asset Management Corp raised its holdings in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after acquiring an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new position in Vaxcyte during the 2nd quarter worth about $70,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.